Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward Phase 3 talks with the FDA.
Martin Babler, Alumis CEO
September 1, 2026 10:24 AM EDT
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward'
Andrew Dunn
Senior Biopharma Correspondent
Alumis’ TYK2 drug fails in key lupus study
Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
ESC: AZ, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions…
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with…
Alnylam's stock is down 30% in 2026 despite Amvuttra's success. Wainua's Phase 3 failure raised doubts about RNAi silencers like…
Three years after gaining three liver disease assets in its $952 million buyout of Alb | Three years after gaining three liver…
An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.
Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered…
